PD-L1 expression in triple-negative breast cancer. - Wikidata - wikimedia - TriplyDB

PD-L1 expression in triple-negative breast cancer.

PD-L1 expression in triple-negative breast cancer.

http://www.wikidata.org/entity/Q37724790

about

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance Checkpoint Inhibitors and Their Application in Breast Cancer Tumor-intrinsic oncogene pathways mediating immune avoidance Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Clinical significance of tumor-infiltrating lymphocytes in breast cancer Current advances in biomarkers for targeted therapy in triple-negative breast cancer PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond Anti-programmed cell death protein-1/ligand-1 therapy in different cancers Identification of Biomarkers for Breast Cancer Using Databases.Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Emerging therapies for breast cancer Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.The immune microenvironment of breast ductal carcinoma in situ.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.Prognostic and predictive value of PDL1 expression in breast cancer.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.

P2860

Q26738729-A2BC7849-E0CC-4AD4-9C93-BC21AF0371D0 Q26739246-A07DF575-B689-40DF-82B1-F5B67032DEAA Q26745442-3F6303AB-F264-4DF9-8A9D-36AF6F26B510 Q26747707-6B209793-F6B4-4499-8DE7-1C3DB9BD5D37 Q26747792-1BE1F5DB-9CEA-4C04-9752-7E94BB9A0859 Q26996518-14267B90-3E5A-417C-BE20-66DA6A620B47 Q28070214-034DA201-9054-4BA2-9C36-42F59EEC029E Q28074202-EB3D6895-34C0-45E5-B3DE-40EBB150B8C2 Q28075712-017DE3B8-9DF2-4C77-8867-A78FF4FBA556 Q28075719-0CA6785F-A4C1-46A7-9511-0537943C5ED7 Q28077815-0FCC5B43-C944-4319-BC74-A3FCEE7374FC Q28082259-422E6646-804C-4995-A701-38EC3EF74A23 Q30239810-4B124408-C9BD-4576-9990-023453F670AE Q30276874-FA37C9FD-CCD1-4597-A8E3-F12AFAFA4D1D Q33275611-DD27F0C4-2337-4F0A-8103-3DEB90AD3B6D Q33276035-8385DA6E-C4D0-4625-8839-35997437394C Q33276164-3CCC5270-7819-4C59-86AD-A0CC1F54D5E3 Q33591876-CEFA1AFC-A5FB-49C5-AADD-842DFED7B901 Q33617949-3F894419-4AB5-4881-ABB6-EBE7BCC5C17F Q33648621-5AF57711-4D27-41E7-A8ED-D5C0DC895CE1 Q33769821-064F28C5-E2F7-4151-B6EF-16C43C05CE39 Q33834968-2EC7FA8F-66EF-4F76-BAA3-4124818CC6A0 Q33887682-0ABC707B-6C50-4802-BCBB-E7A7BA0840FB Q33915040-EA586072-9EAA-4222-AE27-6241D2BC9D28 Q34476337-A0E04F40-FD63-4E06-9219-AB7202EA6463 Q35681604-604E6DD4-DE1C-473F-B67E-E4370685D648 Q35741710-C2D9CE1C-1E81-4C7F-BC07-63209D78EE51 Q35815273-2A268582-F138-4871-B5C3-D29555250BEF Q35922960-636959F9-D123-46ED-9949-8079BAE8C87A Q35938555-04A650A1-7F15-4C10-A97E-E89EC75A2F76 Q35955369-E3766B50-83E2-4213-A5A2-7D6053D2D436 Q36030084-E386DA16-6376-4468-A5F3-70161014C565 Q36045037-7291D70F-EDCC-4775-94D9-1A7BEF087B57 Q36060283-5913CB93-4322-4B6A-96EA-A3B7C9A0BCAD Q36413493-0ABBED2E-B6A4-4728-9D88-A81FE6473FE3 Q36545353-0798CA58-C20B-4A2F-85E7-D744E3E3A9D6 Q36652112-40B8525A-872B-4300-960D-D493A6FB04A6 Q36673469-977E897B-C1A0-48A7-A22B-A74B015AD820 Q36693087-2D963BC9-ABC0-49F4-9A16-81A48CBEBDF8 Q36882550-0AF20517-9EED-4CF7-A011-3440DDB46A4C

P2860

PD-L1 expression in triple-negative breast cancer.

http://www.wikidata.org/entity/Q37724790

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PD-L1 expression in triple-negative breast cancer.

@en

PD-L1 expression in triple-negative breast cancer.

@nl

type

label

PD-L1 expression in triple-negative breast cancer.

@en

PD-L1 expression in triple-negative breast cancer.

@nl

prefLabel

PD-L1 expression in triple-negative breast cancer.

@en

PD-L1 expression in triple-negative breast cancer.

@nl

P1433

Q37724790-168DF1AC-31E6-4A20-BB3D-1335A5A219EC

P1476

Q37724790-E7C91A90-03C3-49F9-8A5D-A72E6ACFA2BD

P2093

Q37724790-02EAC730-8B39-4CF7-9E48-F332EE367F34

Q37724790-1E12A8EB-5578-4521-B0F3-1E22518FBD0B

Q37724790-2C46ADDA-001C-4390-8071-BFAE5B34D2BF

Q37724790-37550E59-21F7-4F54-8A87-782F475A9EBA

Q37724790-4A14134E-0E22-4674-B2AB-0899AB376D4E

Q37724790-4FA5DA81-CE01-487D-B985-250196A0DDB5

Q37724790-6EB43E11-0DD1-4945-85FB-BA062B611A25

Q37724790-71D1DE0F-4C57-48F7-85D9-833C1D503F61

Q37724790-77AD1C90-BF0C-41A4-86F5-EA98DC47E74F

Q37724790-7DE4C8E9-9B95-4DAB-9910-525C2F09C775

P2860

Q37724790-15311BA8-792E-4DC1-81D8-82E6BEF77AAA

Q37724790-21B083BC-54FB-4F78-ADCB-3B8089ADCB55

Q37724790-2EC91AE1-9674-4492-8673-D66D939581FB

Q37724790-331A5CB1-C7C4-407D-8D9E-E76EA729B209

Q37724790-35C533AD-612D-460A-86C5-A5CA9CE9B7B1

Q37724790-3CAD350B-E9BF-4147-BEE3-489A4C9C2CF7

Q37724790-3DB25187-5E6C-453D-B5B4-2951992C57B3

Q37724790-3E186FA0-40CF-41FA-BA27-DF66287C5A5E

Q37724790-432AC399-5317-4C5F-B522-8D5E8B541803

Q37724790-4AC9EDD5-06A0-4FEE-A593-8887229CA0EF

P304

Q37724790-3C6ACD06-50FD-4292-A95B-50560E803C8D

P31

Q37724790-26F0D0BC-985A-406C-BDCF-ABF3EEF8F73D

P356

Q37724790-EA168DFD-BBAB-4FCD-A610-C39879C08F05

P433

Q37724790-9A785C2A-9C2A-416D-88F0-80B36E8E6BC7

P478

Q37724790-AA8E4D40-23AC-43C8-9E47-BAFA7DD190DA

P50

Q37724790-91D0FEF2-AD4C-4BF8-A1BF-DCB4B2B0740E

P577

Q37724790-3D01A4CE-AB19-4958-BC21-516BA21330B2

P5875

Q37724790-CF7ECCD0-E537-4BFB-B0EC-72057C6C9D51

P698

Q37724790-2176C4D9-9F28-48A9-8F9F-7256D56580DA

P932

Q37724790-B3C1D130-B13D-4364-98C2-209B5A149C6A

P356

2326-6066.CIR-13-0127

P1433

Cancer immunology research

P1476

PD-L1 expression in triple-negative breast cancer.

@en

P2093

Akhil Chawla

http://www.w3.org/2001/XMLSchema#string

Ana M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

Anne V Philips

http://www.w3.org/2001/XMLSchema#string

Argun Akcakanat

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Mittendorf

http://www.w3.org/2001/XMLSchema#string

Gheath Alatrash

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Molldrem

http://www.w3.org/2001/XMLSchema#string

Jennifer K Litton

http://www.w3.org/2001/XMLSchema#string

Michael Curran

http://www.w3.org/2001/XMLSchema#string

Na Qiao

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Hallmarks of Cancer: The Next Generation

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

Comprehensive molecular portraits of human breast tumours

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

P304

361-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-13-0127

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Funda Meric-Bernstam

P577

2014-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261883164

http://www.w3.org/2001/XMLSchema#string

P698

24764583

http://www.w3.org/2001/XMLSchema#string

P932

4000553

http://www.w3.org/2001/XMLSchema#string